Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Schuind

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Human Vaccines|November 4, 2011
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 yearsMark H Einstein, Mira Baron, Myron J Levin, et al.
The Pediatric Infectious Disease Journal|July 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging StudyJoon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 5, 2011
Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional studyCecilia M Roteli-Martins, Newton S de Carvalho, Paulo Naud, et al.
Lancet (London, England)|November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
BMJ Open|August 28, 2016
Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trialAgnihotram V Ramanakumar, Paulo Naud, Cecilia M Roteli-Martins, et al.
Human Vaccines & Immunotherapeutics|February 19, 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trialsJoon Hyung Kim, John Diaz-Decaro, Ning Jiang, et al.
The Pediatric Infectious Disease Journal|October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve ChildrenCarine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
The Lancet. Infectious Diseases|August 11, 2019
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysisAlemnew F Dagnew, Osman Ilhan, Won-Sik Lee, et al.
Vaccine|March 18, 2018
Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network)Michaela K Nichols, Melissa K Andrew, Todd F Hatchette, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2021
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70Céline Boutry, Andrew Hastie, Javier Diez-Domingo, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Human Vaccines|November 4, 2011
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 yearsMark H Einstein, Mira Baron, Myron J Levin, et al.
The Pediatric Infectious Disease Journal|July 21, 2021
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging StudyJoon Hyung Kim, Mamadou Drame, Thanyawee Puthanakit, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 5, 2011
Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional studyCecilia M Roteli-Martins, Newton S de Carvalho, Paulo Naud, et al.
Lancet (London, England)|November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
BMJ Open|August 28, 2016
Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trialAgnihotram V Ramanakumar, Paulo Naud, Cecilia M Roteli-Martins, et al.
Human Vaccines & Immunotherapeutics|February 19, 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trialsJoon Hyung Kim, John Diaz-Decaro, Ning Jiang, et al.
The Pediatric Infectious Disease Journal|October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve ChildrenCarine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
The Lancet. Infectious Diseases|August 11, 2019
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysisAlemnew F Dagnew, Osman Ilhan, Won-Sik Lee, et al.
Vaccine|March 18, 2018
Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network)Michaela K Nichols, Melissa K Andrew, Todd F Hatchette, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2021
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70Céline Boutry, Andrew Hastie, Javier Diez-Domingo, et al.
Pageof 6